Brazil · Delayed Price · Currency is BRL Oncoclínicas do Brasil Serviços Médicos Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 saw a 25% drop in gross revenue and a net loss of BRL 275 million, mainly due to medication supply issues and high financial expenses. Adjusted EBITDA turned positive, and cost-cutting measures are underway to support gradual recovery.
-
Q1 2026 saw operational and financial pressures, with revenue hit by medication shortages and a one-time spike in doubtful accounts provisioning. Cost controls and capital discipline are underway, but leverage increased and cash flow was negative.
Fiscal Year 2025
-
Leadership transition and strategic refocus led to a 7% revenue decline and over 30% drop in EBITDA, driven by major client losses and liquidity events. Debt restructuring and asset sales are underway, with ongoing creditor negotiations.
-
Significant restructuring and a BRL 1.4 billion capital increase enabled a return to core oncology, improved margins, and reduced leverage. Asset sales and operational efficiencies drove sequential EBITDA and cash flow gains, with guidance for double-digit growth and lower CapEx.
-
Q2 2025 saw stable gross revenue and a 38.3% sequential rise in adjusted EBITDA, but net loss and negative cash flow persisted due to client discontinuations and high financial expenses. Revenue is expected to decelerate in Q3 as major contracts end, but new client growth and margin recovery are anticipated.
-
Revenue and margins were pressured by a strategic reduction in exposure to certain payers, resulting in slower growth and margin compression, but cash flow and working capital improved. Cost-saving initiatives and new partnerships are expected to support future recovery and margin stabilization.
Fiscal Year 2024
-
2024 was a year of transition, with improved capital structure, reduced net debt, and a focus on cash generation. Margins were impacted by restructuring and sector challenges, but new partnerships and operational efficiencies are expected to drive margin recovery and growth in 2025.
-
Q3 2024 saw a major turnaround to positive free cash flow, driven by improved receivables, cost discipline, and restructuring. Revenue and procedures grew organically, while leverage and working capital improved. Focus remains on cash generation and efficiency.
-
Q2 2024 saw 16% revenue growth and improved margins, driven by higher procedure volumes and disciplined cost control. Leverage dropped to 2.5x net debt/EBITDA after a BRL 1.5 billion capital increase, with further deleveraging targeted. Receivables risk was reduced through a major renegotiation.